Abstract
Molds are ubiquitous in our environment and are considered by the population to be the most important indoor pollutant problem [1]. The current 2023 update to the AWMF mold guideline [1] is intended to allay or channel fears and provide assistance for a sensible diagnosis and treatment decision.
The detection of an IgE-mediated allergy implies for allergists Allergen immunotherapy (AIT) as an established treatment option. However, compared to the well-validated AIT with pollen and house dust mites, the decision to use AIT with mold extracts must be weighed more heavily between the benefits and risks.
Spores of Alternaria alternata are found in high concentrations in the outdoor air. Due to the high allergenic potential and the small size of the spores, an Alternaria allergy often leads to bronchial asthma, especially in children. The effectiveness of AIT with Alternaria extracts has been tested in several studies; for other molds, especially those from the indoor environment, the efficacy and applicability is very limited.
In terms of differential diagnosis, it must be borne in mind that molds can not only cause common allergic reactions but can also be responsible for allergic bronchopulmonary mycoses/aspergillosis (ABPA), Aspergillus bronchitis, exogenous allergic alveolitis (EAA), invasive aspergillosis, mycoses and rhinosinusitis. Very high concentrations, which can occur particularly in workplaces, can also result in toxic effects (“organic dust toxic syndrome”); molds are also held responsible for mucous membrane irritation, odor effects and mood disorders [1].
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The effectiveness of allergen immunotherapy (AIT) in the treatment of IgE-mediated inhalation allergies is undisputed. In the case of IgE-mediated mold allergies, the benefits of this therapy are sometimes controversially discussed among experts, especially when it comes to allergies by mold species which are mainly found in the indoor environment. Particularly in the case of indoor mold exposure, other health effects of mold exposure must be differentiated from common IgE-mediated reactions.
There are only reliable clinical studies on the effectiveness of AIT for IgE-mediated mold allergies for Alternaria alternata, which is predominantly found in outdoor air.
In the following, the outdoor and indoor air, the respective exposure to mold fungi and the therapeutic options of AIT are considered.
Outdoor molds
In studies and reviews on sensitization to molds in the general population, in children and adults, sensitization to Alternaria alternata and, albeit with a lower frequency, to Cladosporium herbarum, have been detected most frequently [2, 3]. The article by T. Gabrio and G. Fischer in this issue is dedicated to this topic.
Alternaria alternata is a potent allergen in outdoor air worldwide. Publications on this can be found, for example, from the USA, United Kingdom, Japan, Mexico, Australia, New Zealand, Poland and Spain. In a summary from 2022, the prevalence of sensitization to Alternaria is estimated at 23.5% in Greece, 20% in Spain and 13% in the USA [4]. Such figures are not available for Germany, but a prevalence in the order of 6–7% can be assumed.
Allergies to mold spores in the outside air are often underestimated, as the symptoms are often not attributed to mold allergy, but to sensitization to competing allergens such as grass and herb pollen.
The current 2023 update to the AWMF mold guideline [1] positions itself on this question as follows “The most common triggers of IgE-mediated rhinitis are allergens from molds that are predominantly found in the outside air, namely primarily Alternaria alternata, and much less frequently Cladosporium herbarum, Botrytis cinerea, Mucor spp., Penicillium spp. and Aspergillus spp.” [1]. In addition to spores, fragments of mycelium filaments also act as allergens, which, like spores, are found in the air as allergen carriers [5].
Alternaria alternata is particularly important for inhalation allergies in the outdoor air. In Germany, depending on the season and climatic conditions as well as vegetation and agricultural use, there are different levels of Alternaria alternata. The highest concentration of Alternaria spores or their fragments is found in rural areas with predominantly cereal cultivation, including maize, in regions with rapeseed cultivation, before the harvest, as the grains ripen, during the harvest (additional high concentration of spore fragments) and in the vicinity of pasture and meadow areas (hay mowing). Allergy symptoms can be expected from a threshold value of 100 spores/m3. The dependence of the concentration of Alternaria spores on weather conditions can be illustrated by evaluating the data from the Treuenbrietzen pollen trap over a period of ten years (Fig. 1).
June, July and August are the months with the highest concentration of airborne Alternaria spores. Competing allergens are grass pollen with a main load from June to mid-July and mugwort pollen with a main load from mid-July to the end of August. For this reason, allergy sufferers with symptoms during these periods often misinterpret the results of tests: Sensitization to pollen is assumed to be the trigger rather than Alternaria alternata being thought to be the cause. Figure 2 shows not only Alternaria spores but also fragments of Alternaria spores on 1 day in August in the pollen trap from Treuenbrietzen.
Increased allergen formation and increased allergen release has been described as a result of increasing CO2 exposure [6], as well as storms and thunderstorms and when frequent and heavy rain showers alternate with sunshine in summer. During extreme weather events, intact spores and fungal mycelium can be fragmented and are a major cause of asthma and exacerbation of pre-existing asthma [7,8,9,10,11,12,13,14].
A contribution by Pulimood et al. [15] should be mentioned as an example: The group gave an odds ratio for sensitization to Alternaria and asthma attacks during thunderstorms of 9.31 and defined the threshold concentration for triggering allergic symptoms as > 100 Alternaria alternata spores/m3, > 10 Alternaria alternata spore fragments/m3 and > 50 grass pollen/m3. The publication shows a higher number of stationary exposures with an increased number of spore fragments in the air (2.2-fold increase).
The current 2023 update to the AWMF mold guideline [1] positions itself as follows: “The genus Alternaria alternata (formerly A. tenuis), which is to be evaluated as an outdoor mu, appears to be a mold that is particularly important for the development and severity of asthma. A temporal relationship between asthma symptoms and Alternaria spore concentration could be shown, especially in patients with a high degree of sensitization and in patients with and without concomitant grass pollen allergy” [1].
At the Johanniter Hospital in Treuenbrietzen, the author of this article has been investigating the allergological significance of Alternaria alternata as an outdoor aeroallergen since the early 1990s. An evaluation of 1260 patients who were examined as outpatients for allergy complaints in 2020 showed that 6.1% (77 patients) were sensitized to Alternaria alternata (positive skin test and/or detection of allergen-specific IgE antibodies). 67 (87%) of these 77 have been challenged (nasal, conjunctival and/or bronchial challenge test). The challenge test was positive in 41 patients (61%). It can therefore be assumed that at least 3.2%, i.e. 41 of 1260 patients, suffered from a clinically relevant allergy Alternaria alternata, and had an indication for Alternaria alternata AIT. In 62 of the 77 sensitized patients a bronchial provocation with histamine was performed additionally, giving the diagnosis of non-specific bronchial hyperreactivity in 54 patients (87%). Some of these patients had previously not been diagnosed with asthma.
Furthermore, it was found that 37 of the patients sensitized to Alternaria alternata were simultaneously sensitized to grass pollen. 29 of these 37 patients were subjected to a provocation with grass pollen. In ten patients, both the provocation with Alternaria alternata and grass pollen were positive, which means that AIT with Alternaria alternata and grass pollen u.
AIT with Alternaria
As with all other mold extracts, Alternaria alternata extracts for AIT are obtained by extraction of molds kept in culture; the literature also reports on studies in which native, purified Alt a 1 [16] was used; animal experiments were also carried out with recombinantly produced Alt a 1 [17]. The problems associated with the production of allergen extracts from molds are discussed by M. Raulf and S. Kespohl in their article in this issue.
In contrast to other allergologically relevant molds, Alternaria alternata has one dominant major allergen, Alt a 1, with a sensitization frequency of 90% [4], comparable to Bet v 1 from birch (> 90%) and Fel d 1 from cat (> 90%). Alternaria alternata extracts for diagnostics and therapy are standardized for this major allergen; due to the dominance of this one allergen, studies on the efficacy of immunotherapy with Alt a 1 have also been conducted.
Another allergological relevant mold in the outdoor environment is Cladosporium herbarum. In contrast to Alternaria alternata, no dominant major allergen has been described for Cladosporium herbarum. Some allergen components in Cladosporium herbarum and Alternaria alternata extracts (Table 1) show a high degree of homology, which causes some cross-reactivity between different molds [18].
The clinical efficacy and tolerability of Alternaria alternata AIT has been demonstrated in several clinical trials in children and adults [19,20,21,22,23,24]. Systemic side effects as treatment-related adverse events due to AIT with mold extracts occurred in 26.1% of treated patients in a meta-analysis of published studies, with a majority of side effects due to the treatment with Cladosporium extracts [24].
If there is evidence of relevant sensitization to Alternaria and grass pollen, AIT with two allergen extracts, in this case grass pollen and Alternaria alternata, can be considered for selected patients. In Germany, such allergen mixtures are not permitted under TAV; treatment is carried out using two separate extracts.
Indoor molds
The detection of relevant mold concentrations in the indoor environment is complicated. There are no reliable measurable parameters in the air or on surfaces that allow a valid evaluation. In this issue, T. Gabrio and G. Fischer have dealt with this problem in detail.
The diagnosis of IgE-mediated inhalation allergy caused by indoor molds is a challenge. In their article in this issue, M. Raulf and S. Kespohl discuss this problem. Aspergillus spp. frequently found indoor are contain a high number of allergen components. For Aspergillus fumigatus, 30 different allergen components have been described [18]. Five recombinant components (Asp f 1, 2, 3, 4, 6) are currently available for diagnostic purposes, but these are of little help in the diagnosis of clinically relevant inhalative allergies and in particular to decide on AIT. In contrast to a sensitization frequency of 90% against Alt a1 in Alternaria allergy sufferers, little is known about the prevalence of sensitization to the components of other molds.
The production of well-characterized and standardized extracts, particularly from Aspergillus species, is problematic as the allergen spectrum of the fungus changes relatively quickly in culture. However, a prerequisite for the efficacy of AIT is that all components to which a patient is sensitized are contained in the allergen extract. This requires an analysis of the sensitization spectrum of the patient and a molecular characterization of therapeutic extracts—further studies are essential. Currently, the indication for AIT in cases of allergy to indoor molds should be made with great caution.
The majority of proven mold sensitization cases have few therapeutic consequences, except for the detection of sensitization to Alternaria alternata. The possibilities of sound diagnostics depend on our scientific knowledge and in particular on the availability of high-quality diagnostics, as reported in the article in this issue by M. Raulf and S. Kespohl, who have a detailed diagnostic algorithm.
The differential diagnostic assessment of health impairments due to indoor molds has yet another facet. In addition to the allergen carriers spores and mycelium fragments, cell wall components such as β‑1,3‑glucans and chitins, mycotoxins and MVOC (“microbial volatile organic compounds”) are particularly relevant to the health of atopic patients [1]. Allergies to molds are only rarely the cause of the health impairment of atopic people due to moisture damage in indoor spaces. Inflammatory processes on the mucous membranes of the upper and lower respiratory tract as a result of moisture damage in indoor spaces can also be triggered in atopic patients by non-IgE-mediated mast cell activation. VOCs and proteases are candidates for this. Proteases also increase the activity of Th-2 cells, for example in the case of a concomitant mite allergy. Irritants (β‑1,3‑glucans, chitins, mycotoxins) can activate C‑nerve fibers and cough receptors in the inflamed mucous membrane. This results in symptoms such as dry cough, asthma, rhinitis, sneezing and conjunctivitis, which can be misinterpreted as an allergic reaction. J. Hurraß, B. Heinzow and G. Wiesmüller have published a detailed article on this topic in this issue.
Conclusion for practice
Molds, in particular Alternaria alternata and Cladosporium herbarum, are important outdoor allergens. Due to the frequent polysensitization of allergy sufferers and overlapping exposure times, test results must be critically evaluated. There is good evidence in the literature for the efficacy of AIT, particularly with Alternaria extracts.
Indoor mold is considered an important indoor problem by the general public, but the detection of relevant indoor mold contamination is problematic. The most important consequence of the detection of mold in indoor spaces is adequate remediation, which requires clarification of the cause of increased mold growth and, if necessary, structural measures.
Abbreviations
- ABPA:
-
Allergic bronchopulmonary aspergillosis
- AIT:
-
Allergen immunotherapy
- EAA:
-
Exogenous allergic alveolitis
- MVOC:
-
Microbial volatile organic compounds
References
Hurraß J, Heinzow B, Walser-Reichenbach S, Aurbach U, Becker S, Bellmann R et al. S2k Leitlinie „Medizinisch klinische Diagnostik bei Schimmelpilzexposition in Innenräumen“ Update 2023 AWMF-Register-Nr. 161/001. https://go.sn.pub/awmf/schimmelpilzleitlinie; Stand: 15 Apr 2024
Forkel S, Beutner C, Schröder SS, Bader O, Gupta S, Fuchs T, et al. Sensitization against fungi in patients with airway allergies over 20 years in Germany. Int Arch Allergy Immunol. 2021;182:515–32.
Zöllner I, Gabrio Th, Weidner U, Horras-Hun G, Gottfried A, Hack U, et al. Sensibilisierung gegenüber Schimmelpilzen bei Erwachsenen in. In: Wiesmüller GA, Heinzow B, Herr CEW, editors. 11 in. Württemberg, Vol. 2010. Baden: Gesundheitsrisiko Schimmelpilze im Innenraum. Landsberg: ecomed Medizin; 2013.
Sἀnchez P, Velez-del-Burgo A, Suñen E, Martinez J, Postigo I. Fungal Allergen and Mold Diagnosis: Role and Relevance of Alternaria alternate Alt a 1 Protein Family. J Fungi. 2022;8:277.
Molecular Allergology User’s Guide 2.0. https://go.sn.pub/maug_2_0; Stand: 15 Apr 2024
Wolf J, O’Neill NR, Rogers CA, Muilenberg ML, Ziska LH. Elevated Atmospheric Carbon Dioxide Concentrations Amplify Alternaria alternate Sporulation and Total Antigen Production. Environ Health Perspect. 2010;118:1223–8.
Black P, Udy AA, Brodie SM. Sensitivity to fungual allergens is a risk factor for life-threatening asthma. Allergy. 2000;55:501–4.
Bush KR, Prochnau JJ. Alternaria-induced asthma. J Allergy Clin Immun. 2004;113:227–34.
Chooniedass R, et al. The Risk of Asthma in Children Sensitized to Alternaria. J Allergy Clin Immun. 2007;120:186.
Downs SH, Mitakakis TZ, Marks GB, Car NG, Belousova EG, Leüppi JD, et al. Clinical Importance of Alternaria Exposure in Children. Am J Respir Crit Care Med. 2001;164:455–9.
Perzanowski MS, Sporik R, Squillace SP, Gelber LE, Call R, Carter M, et al. Association of Sensibilisation to Alternaria allergens with asthma among school-age children. J Allergy Clin Immun. 1998;101:626–32.
Zureik M, Neukirch C, Leynaert B, Liard R, Bousquet J, Neukirch F. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ. 2002;325:411.
D’Amato G, Annesi-Maesano I, Vaghi A, Cecchi L, D’Amato M. How Do Storms Affect Asthma? Curr Allergy Asthma Rep. 2018;18:24.
Marks GB, Bush RK. It’s blowing in the wind: New insights into thunderstorm-related asthma. J Allergy Clin Immunol. 2007;120:530–2.
Pulimood TB, Corden JM, Bryden C, Sharples L, Nasser SM. Epidemic asthma and the role of the fungal mold Alternaria alternata. J Allergy Clin Immun. 2007;120:610–7.
Tabar AI, Prieto L, Alba P, Nieto A, Rodríguez M, Torrecillas M, et al. Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1. J Allergy Clin Immunol. 2019;144:216–23.
Liu J, Yin J. Immunotherapy With Recombinant Alt a 1 Suppresses Allergic Asthma and Influences T Follicular Cells and Regulatory B Cells in Mice. Front Immunol. 2021;12:747730.
Allergen-Nomenklatur WHO/IUIS-Unterausschuss für Allergen-Nomenklatur. https://allergen.org..
Cantani A, Businco E, Maglio A. Alternaria allergy: A three-year controlled study in children treated with immunotherapy. Allergol Immunopathol (madr). 1988;16:1–4.
Horst M, Hejjaoui A, Horst V, Michel F‑B, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immun. 1990;85:460–72.
Rabe U, Wolf H, Bockmeyer M, Schnitker J. Verträglichkeit und Therapieeffekt der spezifischen Immuntherapie mit einem standardisierten Alternaria-alternari-Allergenpräparat. Allergo J. 2005;14:125–33.
Tabar AI, Lizazo MT, Garcia BE, Gomez B, Echechipia S, Aldunate MT, et al. Double-blind, placebo-contolled study of Alternaria alternata immunotherapy:Clinical efficacy and safty. Pediatr Allergy Immunol. 2008;19:67–75.
Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol. 2011;127(6):502–508.e1.
Di Bona D, Frisenda F, Albanesi M, Di Lorenzo G, Caiaffa MF, Macchia L. Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review. Clin Exp Allergy. 2018;48:1391–401.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
R. Brehler reports personal fees from AeDA, ALK, Allergopharma, Almirall, Apothekerkammer Westfalen-Lippe, Astra Zeneca, Behring, Bencard, DGP, DIATER, ECM Expo&Conference Management GmbH, Forum für med. Fortbildung FomF GmbH, GSK, HAL, Leti, Lilly, MedUpdate, Merck, Novartis, Omnicuris, RG-Gesellschaft für Information und Organisation mbH, Sanofi, Stallergenes, Takeda, Thermo-Fischer outside the submitted work. U. Rabe declare that there are no conflicts of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Brehler, R., Rabe, U. Allergen-specific immunotherapy for mold allergies. Allergo J Int 33, 101–105 (2024). https://doi.org/10.1007/s40629-024-00293-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40629-024-00293-w